Fu Peng
- Cancer Research top 5%
- MicroRNA in disease regulation 9
- Cancer-related molecular mechanisms research 8
- Pharmacology top 5%
- Pharmacological Effects of Natural Compounds 4
- Molecular Biology top 10%
- Natural product bioactivities and synthesis 5
- Circular RNAs in diseases 4
- Biochemistry top 10%
-
- Cancer Mechanisms and Therapy 5
-
- Essential Oils and Antimicrobial Activity 5
-
- Ferroptosis and cancer prognosis 4
- Journals
- International Journal of Molecular Sciences (6 papers)Journal of Ethnopharmacology (4 papers)The American Journal of Chinese Medicine (4 papers)
- Partner nations
- ChinaMacaoUnited Kingdom
In The Last Decade
Fu Peng
50 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 113
- Cancer Research 320
- Pharmacology 158
- Complementary and alternative medicine 98
- Molecular Biology 772
- Biochemistry 60
Countries citing papers authored by Fu Peng
This map shows the geographic impact of Fu Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fu Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fu Peng more than expected).
Fields of papers citing papers by Fu Peng
This network shows the impact of papers produced by Fu Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fu Peng. The network helps show where Fu Peng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fu Peng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 3 | |
| 5 | 2025 | 1 | |
| 6 | 2024 | 13 | |
| 7 | 2024 | 6 | |
| 8 | 2024 | 12 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 46 | |
| 11 | 2023 | 7 | |
| 12 | 2023 | 16 | |
| 13 | 2023 | 37 | |
| 14 | 2022 | 28 | |
| 15 | 2022 | 48 | |
| 16 | 2021 | 19 | |
| 17 | 2021 | 47 | |
| 18 | 2021 | 21 | |
| 19 | 2021 | 17 | |
| 20 | 2021 | 27 |
About Fu Peng
Fu Peng is a scholar working on Pharmacology, Cancer Research, Toxicology, Complementary and alternative medicine and Molecular Biology, having authored 55 papers that have together received 1.4k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (8 papers), Natural product bioactivities and synthesis (5 papers), Cancer Mechanisms and Therapy (5 papers), Essential Oils and Antimicrobial Activity (5 papers), Ferroptosis and cancer prognosis (4 papers), Pharmacological Effects of Natural Compounds (4 papers) and Circular RNAs in diseases (4 papers). The work is most often cited by research in Cancer Research (320 citations), Pharmacology (158 citations), Complementary and alternative medicine (98 citations), Molecular Biology (772 citations) and Biochemistry (60 citations). Fu Peng has collaborated with scholars based in China, Macao and United Kingdom. Frequent co-authors include Cheng Peng, Lei Yu, Jun Xie, Xiaofang Xie, Hailin Tang, Jianping Chen, Qingqing Liu, Junren Chen, Gangmin Li and Yan Chen. Their work appears in journals such as International Journal of Molecular Sciences, Journal of Ethnopharmacology, The American Journal of Chinese Medicine, Phytotherapy Research and Biomedicine & Pharmacotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.